1. Home
  2. MP vs CYTK Comparison

MP vs CYTK Comparison

Compare MP & CYTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo MP Materials Corp.

MP

MP Materials Corp.

HOLD

Current Price

$68.80

Market Cap

9.0B

ML Signal

HOLD

Logo Cytokinetics Incorporated

CYTK

Cytokinetics Incorporated

HOLD

Current Price

$62.50

Market Cap

8.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MP
CYTK
Founded
2017
1997
Country
United States
United States
Employees
N/A
N/A
Industry
Metal Mining
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
9.0B
8.0B
IPO Year
N/A
2004

Fundamental Metrics

Financial Performance
Metric
MP
CYTK
Price
$68.80
$62.50
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
13
16
Target Price
$70.92
$82.38
AVG Volume (30 Days)
7.8M
2.2M
Earning Date
02-19-2026
02-26-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$232,742,000.00
$87,211,000.00
Revenue This Year
$34.68
$339.72
Revenue Next Year
$137.40
$79.08
P/E Ratio
N/A
N/A
Revenue Growth
26.44
2609.26
52 Week Low
$18.64
$29.31
52 Week High
$100.25
$70.98

Technical Indicators

Market Signals
Indicator
MP
CYTK
Relative Strength Index (RSI) 65.02 47.75
Support Level $62.20 $60.30
Resistance Level $70.07 $65.08
Average True Range (ATR) 3.73 2.91
MACD 1.58 -0.01
Stochastic Oscillator 94.24 45.74

Price Performance

Historical Comparison
MP
CYTK

About MP MP Materials Corp.

MP Materials Corp is the producer of rare earth materials in the Western Hemisphere. The company owns and operates the Mountain Pass Rare Earth Mine and Processing Facility, the only rare earth mining and processing site of scale in North America. The company is also developing a rare earth metal, alloy, and magnet manufacturing facility in Fort Worth, Texas. The company's operations are organized into two reportable segments: Materials and Magnetics.

About CYTK Cytokinetics Incorporated

Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.

Share on Social Networks: